CEO Steven Harr was paid $2,903,010 in fiscal year 2025, ↓ down 67.0% from fiscal year 2024 (SEC filing 0001193125-26-174883 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,903,010 ↓ Steven Harr total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
SANA's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Harr | $696,140 | $0 | $425,001 | $1,327,500 | $450,369 | $0 | $4,000 | $2,903,010 |
| President, Chief Executive Officer, and Director | ||||||||
| Bernard Cassidy | 404,034 | 0 | 135,999 | 424,800 | 0 | 0 | 51,280 | 1,016,113 |
| Former Executive Vice President, General Counsel, and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Steven Harr | $2,903,010 | $8,788,580 | $2,671,662 | ↓ −5,885,570 |
| Bernard Cassidy | 1,016,113 | 2,345,597 | 987,382 | ↓ −1,329,484 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Sana Biotechnology's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SANA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses SANA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SANA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alise S. Reicin, M.D | Independent Director | $170,287 |
| Douglas Cole, M.D | Former director (through FY2025) | $20,488 |
| Hans E. Bishop | Chair of the Board | $220,515 |
| Joshua H. Bilenker, M.D | Independent Director | $169,517 |
| Mary Agnes (Maggie) Wilderotter | Former director (through FY2025) | $162,570 |
| Michelle Seitz, CFA | Independent Director | $182,787 |
| Patrick Y. Yang, Ph.D | Independent Director | $167,787 |
| Richard Mulligan, Ph.D | Director | $162,787 |
| Robert L. Rosiello | Independent Director | $230,696 |
| Robert Nelsen | Independent Director | $162,787 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen | Director | 2026-06-04 | A | 90,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua H. Bilenker | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alise Reicin | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michelle Seitz | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Rosiello | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Y. Yang | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Mulligan | Director | 2026-06-04 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-07-06 | A | 6,297 | 0 | 0 | Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-26 | D | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-26 | A | 125,000 | 0 | 0 | Common | Form 4 ↗ |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 2026-08-27 | D | 41,158 | 4 | 169,159 | Common | Form 4 ↗ |
| Hans E. Bishop | Director | 2026-10-05 | A | 8,680 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Steven Harr | RSU | — | — | — | — | — | $425,001 |
| Steven Harr | OPTION | — | — | — | — | — | 1,327,500 |
| Bernard Cassidy | RSU | — | — | — | — | — | 135,999 |
| Bernard Cassidy | OPTION | — | — | — | — | — | 424,800 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Steven Harr | $425,001 | $0 | $1,327,500 | 0.0% |
| Bernard Cassidy | 135,999 | 0 | 424,800 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bernard Cassidy | RSU | 53,333 | — | $217,065 |
| Bernard Cassidy | RSU | 33,126 | — | 134,823 |
| Steven Harr | RSU | 150,000 | — | 610,500 |
| Steven Harr | RSU | 166,667 | — | 678,335 |
| Bernard Cassidy | Option | 240,000 | 2.55 | — |
| Steven Harr | Option | 47,500 | 5.7 | — |
| Steven Harr | Option | 203,125 | 3.76 | — |
| Steven Harr | Option | 750,000 | 2.55 | — |
| Steven Harr | Option | 506,250 | 9.58 | — |
| Bernard Cassidy | Option | 150,000 | 7.13 | — |
| Bernard Cassidy | Option | 43,750 | 3.76 | — |
| Bernard Cassidy | Option | 111,797 | 9.58 | — |
We have a pay-for-performance focused executive compensation philosophy. We believe that compensation should be designed to drive company performance to increase stockholder value. We seek to achieve this by using different elements of compensation and a market-based approach to attract, retain, and motivate a high-performing team of executive officers, and by aligning a majority of the compensation of each of our executives with the company's short- and long-term performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Human Capital Solutions practice) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert L. RosielloIndependent · Audit · Compensation and Talent | $30,119 | $0 | $200,577 | $0 | $0 | $230,696 |
| Hans E. BishopIndependent · Board Chair · Audit · Compensation and Talent (Chair) | 97,727 | 0 | 122,787 | 0 | — | 220,515 |
| Michelle Seitz, CFAIndependent · Audit (Chair) | 60,000 | 0 | 122,787 | 0 | 0 | 182,787 |
| Alise S. Reicin, M.DIndependent · Compensation and Talent | 47,500 | 0 | 122,787 | 0 | 0 | 170,287 |
| Joshua H. Bilenker, M.DIndependent · Nominating and Corporate Governance (Chair) | 46,729 | 0 | 122,787 | 0 | — | 169,517 |
| Patrick Y. Yang, Ph.DIndependent · Nominating and Corporate Governance | 45,000 | 0 | 122,787 | 0 | 0 | 167,787 |
| Robert NelsenIndependent | 40,000 | 0 | 122,787 | 0 | 0 | 162,787 |
| Richard Mulligan, Ph.DNot independent | 40,000 | 0 | 122,787 | 0 | 0 | 162,787 |
| Mary Agnes (Maggie) WilderotterIndependent · Audit · Nominating and Corporate Governance (Chair) · Departed during FY | 39,783 | 0 | 122,787 | 0 | 0 | 162,570 |
| Douglas Cole, M.DIndependent · Compensation and Talent · Departed during FY | 20,488 | 0 | 0 | 0 | 0 | 20,488 |
| Steven D. Harr, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $122,787 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 35,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $467,346 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $467,346 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sana Biotechnology | 2025 | Steven Harr | $696,140 | $425,001 | $1,327,500 | $450,369 | $2,903,010 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Steven Harr | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Summary Compensation Table” · page 25. As printed: 2,903,010. Filing ↗machine: t69 · r3 · c27 · span 235773–235782 |
| 2 | Section 01, Bernard Cassidy | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Summary Compensation Table” · page 25. As printed: 1,016,113. Filing ↗machine: t69 · r6 · c27 · span 241348–241357 |
| 3 | Section 03, Steven Harr RSU | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t69 · r3 · c11 · span 234737–234744 |
| 4 | Section 03, Steven Harr OPTION | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t69 · r3 · c15 · span 234996–235005 |
| 5 | Section 03, Bernard Cassidy RSU | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t69 · r6 · c11 · span 240257–240264 |
| 6 | Section 03, Bernard Cassidy OPTION | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t69 · r6 · c15 · span 240516–240523 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-03 | 0001193125-26-088215 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Robert L. Rosiello | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 230,696. Filing ↗machine: t100 · r8 · c11 · span 375225–375232 |
| 9 | Section 08, Hans E. Bishop | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 220,515. Filing ↗machine: t100 · r3 · c11 · span 369691–369698 |
| 10 | Section 08, Michelle Seitz, CFA | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 182,787. Filing ↗machine: t100 · r9 · c11 · span 376295–376302 |
| 11 | Section 08, Alise S. Reicin, M.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 170,287. Filing ↗machine: t100 · r7 · c11 · span 374075–374082 |
| 12 | Section 08, Joshua H. Bilenker, M.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 169,517. Filing ↗machine: t100 · r2 · c11 · span 368570–368577 |
| 13 | Section 08, Patrick Y. Yang, Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 167,787. Filing ↗machine: t100 · r11 · c11 · span 378475–378482 |
| 14 | Section 08, Robert Nelsen | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 162,787. Filing ↗machine: t100 · r6 · c11 · span 373003–373010 |
| 15 | Section 08, Richard Mulligan, Ph.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 162,787. Filing ↗machine: t100 · r5 · c11 · span 371914–371921 |
| 16 | Section 08, Mary Agnes (Maggie) Wilderotter | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 162,570. Filing ↗machine: t100 · r10 · c11 · span 377402–377409 |
| 17 | Section 08, Douglas Cole, M.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 20,488. Filing ↗machine: t100 · r4 · c3 · span 370262–370268 |
| 18 | Section 08, Steven D. Harr, M.D | DEF 14A | 2026-04-24 | 0001193125-26-174883 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 02, Robert Nelsen 2026-06-04 | Form 4 | 2026-06-05 | 0001770121-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Joshua H. Bilenker 2026-06-04 | Form 4 | 2026-06-05 | 0001612312-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Hans E. Bishop 2026-06-04 | Form 4 | 2026-06-05 | 0001480212-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Alise Reicin 2026-06-04 | Form 4 | 2026-06-05 | 0001757533-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Michelle Seitz 2026-06-04 | Form 4 | 2026-06-05 | 0001836301-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Robert L. Rosiello 2026-06-04 | Form 4 | 2026-06-05 | 0001645041-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Patrick Y. Yang 2026-06-04 | Form 4 | 2026-06-05 | 0001309988-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Richard Mulligan 2026-06-04 | Form 4 | 2026-06-05 | 0001376247-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Hans E. Bishop 2026-07-06 | Form 4 | 2026-07-07 | 0001480212-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Dhavalkumar Dhirajlal Patel 2026-08-26 | Form 4 | 2026-08-27 | 0002115339-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Dhavalkumar Dhirajlal Patel 2026-08-26 | Form 4 | 2026-08-27 | 0002115339-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Dhavalkumar Dhirajlal Patel 2026-08-27 | Form 4 | 2026-08-27 | 0002115339-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Hans E. Bishop 2026-10-05 | Form 4 | 2026-10-06 | 0001480212-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 33 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 34 | Section 09b board cost (computed) | Computed | — | — | Cash 467,346 + equity 0 + all other 0 = 467,346, summed across the director compensation table rows.machine: formula: Σ = 467,346 |
| 35 | Sana Biotechnology (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174883 | CEO total compensation as printed in Sana Biotechnology's own proxy. As printed: 2,903,010. Filing ↗machine: t69 · r3 · c27 · span 235773–235782 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.